[Retracted] C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis

Table 1

Main characteristics of studies included in this meta-analysis.

First author, publication year	Country	Recruitment period	Age (mean/median) yr	No. pts	Cancer type	Pathology	Stage	Survival analysis	Mean/median months of follow-up	NOS scores
Schmid et al. 2007 [36]	Austria	1995–2005	NM	403	EC	ADC	FIGO I-IV	OS,DFS	NM	6
Six et al. 2008 [33]	Austria	1995–2003	69.1	67	VC	SCC	FIGO I-IV	OS,DFS	NM	7
Hefler et al. 2008 [28]	Austria	NM	60.5	623	OC	Serous, mucinous, endometrioid, clear cell, and others	FIGO I-IV	OS	25.5	7
Stephan et al. 2011 [23]	Austria	2000–2009	49.2	178	CC	SCC and non-SCC	FIGO I-IV	OS,DFS	46	8
Dobrzycka et al. 2013 [27]	Poland	2003–2007	57.6	118	OC	Serous, mucinous, endometrioid, clear cell, and others	FIGO I-IV	OS,DFS	24.63	8
Nakamura et al. 2015 [21]	Japan	2005–2014	52.6	32	CC	SCC and non-SCC	NM	OS	NM	7
Zhang et al. 2015 [29]	China	2000–2012	50.6	190	OC	Serous, mucinous, endometrioid, clear cell, and others	FIGO I-IV	OS,PFS	43	8
Lu et al. 2015 [31]	China	2006–2010	55.28	107	OC	serous, mucinous, endometrioid, clear cell, and others	FIGO I-IV	OS	28.5	8
Li et al. 2015 [34]	China	2007–2009	53	282	EC	Endometrioid and others	FIGO I-IV	DSS	51.2	8
Xiao et al. 2015 [26]	China	2004–2011	52	238	CC	SCC, non-SCC	FIGO IB1-IVA	OS,PFS	42	8
Bodner–Adler et al. 2016[19]	Austria	2005–2015	51	46	CC	ADC	FIGO I-IV	OS	NM	7
Liu et al. 2017 [32]	China	2006–2012	53	200	OC	Serous, mucinous, endometrioid, clear cell, and others	FIGO I-IV	OS	NM	8
He et al. 2018 [25]	China	2007–2009	69	198	CC	SCC	FIGO I-IV	OS	NM	8
Wang et al. 2019 [24]	China	2012–2014	51.5	110	CC	SCC	FIGO I-II	OS,PFS	NM	8
Wang et al. 2020 [20]	China	2013–2015	59	150	CC	SCC	FIGO IB2,IIA2-IIB, III	OS	39	8
An et al. 2020 [22]	China	2010–2017	45.5	278	CC	SCC, non-SCC	FIGO IB-IIA	OS,RFS	NM	8
Terlikowska et al. 2020[35]	Poland	2006–2012	69	176	EC	ADC	FIGO I-IV	OS	NM	7
Komura et al. 2020[30]	Japan	2007–2016	NM	308	OC	Serous, mucinous, endometrioid, clear cell, others	FIGO I-IV	DSS	NM	6
Njoku et al. 2021 [37]	United Kingdom	2010–2015	66	358	EC	Endometrioid and others	FIGO I-IV	OS,RFS	40	8

Abbreviations: ADC: adenocarcinoma; CC: cervical cancer; DFS: disease-free survival; DSS: disease-specific survival; EC: endometrial cancer; FIGO: International Federation of Gynecology and Obstetrics; NM: not mentioned; OC: ovarian cancer; OS: overall survival; PFS: progress-free survival; RFS: recurrence-free survival; SCC: squamous cell carcinoma; VC: vulvar cancer.